nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-0248473D·Framework v5.13·Pipeline v0.4·Evaluated 19 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Psychiatry and Mental health·Basis: Full text·Type: Randomized controlled trial

Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial.

Wang et al.Wang, Xu, Xu et al.·2026·BMJ (Clinical research ed.)·10.1136/bmj-2026-101209 ↗

Primary claim

no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP and intensive treatment

Well-supported · randomised comparison with masked adjudication and achieved event accrual supports the stated nonsignificant result over the observed follow-up
In brief

A large randomised trial finds no significant cognitive difference between blood pressure targets in type 2 diabetes, with long-term effects unresolved.

ReliabilityCaveats4 of 4 checks completeRead the 3 entries ↓
Likely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

OBJECTIVE: To evaluate the effect of intensive compared with standard treatment of systolic blood pressure (SBP) on cognitive outcomes and brain structures in adults with type 2 diabetes.

DESIGN: Multicentre, open label, outcome assessor masked, randomised controlled trial.

SETTING: 145 clinical centres across seven geographical regions in China.

PARTICIPANTS: 12 821 adults aged ≥50 years with type 2 diabetes, raised SBP, and increased cardiovascular risk, of whom 12 434 without probable dementia at baseline were included in this cognitive ancillary study. Further assessments were performed annually and at the end of study.

INTERVENTIONS: Participants were randomly assigned to receive intensive treatment targeting SBP <120 mm Hg or standard treatment targeting SBP <140 mm Hg for up to five years.

MAIN OUTCOME MEASURES: The primary cognitive outcome was a composite of all cause dementia or mild cognitive impairment. Secondary cognitive outcomes included all cause dementia, mild cognitive impairment, changes in cognitive functions, and changes in brain magnetic resonance imaging (MRI) characteristics. A subset of participants underwent brain MRI at baseline (n=862) and at the end of study (n=605) to assess changes in white matter lesion volume and total brain volume.

RESULTS: 6219 participants were assigned to receive intensive treatment and 6215 to receive standard treatment. Baseline mean age was 63.7 years, and 5567 (44.8%) participants were women. After one year, mean SBP was 121.6 mm Hg in the intensive treatment group and 133.2 mm Hg in the standard treatment group. During a median follow-up of 3.8 years, the primary cognitive outcome of all cause dementia or mild cognitive impairment occurred in 747 participants (3.69 events per 100 person years) in the intensive treatment group and 783 participants (3.89 events per 100 person years) in the standard treatment group (hazard ratio 0.96, 95% confidence interval (CI) 0.86 to 1.06; P=0.38). In the MRI substudy (428 intensive treatment v 434 standard treatment), the intensive treatment group had a smaller increase in white matter lesion volume compared with the standard treatment group (between group difference -0.09 inverse hyperbolic sine (asinh) transformed cm3, 95% CI -0.15 to -0.02; P=0.01).

CONCLUSIONS: Over a median of about four years, no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP (target <140 mm Hg) and intensive treatment (target <120 mm Hg). Intensive treatment was, however, associated with a reduction in the accrual of cerebral white matter lesion volume.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03808311.

Key Claims

Primary finding · Well-supported

no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP and intensive treatment

Likely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

randomised comparison with masked adjudication and achieved event accrual supports the stated nonsignificant result over the observed follow-up

Abstract Conclusions; Results, Table 2, Fig 3
Quote verified
Secondary · Tentative

intensive SBP treatment was associated with a reduction in the accrual of cerebral white matter lesion volume in the MRI substudy

selected MRI participation and 29.8% missing repeat scans leave the estimate dependent on weighting and imputation assumptions

Conclusions
Quote verified
Secondary · Well-supported

no statistically significant between group differences were observed for changes in global cognitive function (mean between group difference 0.011 standardised units, 95% CI -0.009 to 0.031; P=0.28)

longitudinal randomised comparison with high assessment retention and consistent sensitivity analyses supports the reported nonsignificant difference

Results, Cognitive assessment; Table 3
Quote verified
Secondary · Supported

No statistically significant between group difference was observed for changes in total brain volume (between group difference 2.97 cm³, 95% CI -0.86 to 6.81; P=0.13) (table 4).

selected substudy participation and missing repeat scans limit the scope of the reported nonsignificant comparison

Results, MRI outcomes; Table 4
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Large trial addresses a diabetes evidence gap

The cognitive cohort included 12,434 adults and accrued 1,530 adjudicated composite events, exceeding the 1,374-event target. It supplies a direct comparison in a population excluded from SPRINT MIND and assessed less comprehensively in ACCORD MIND.

↳ Introduction; Statistical analysis; Table 2

#methodological rigour

Masked adjudication supports the randomised comparison

Central randomisation and masked cognitive adjudication support outcome assessment despite open-label treatment. Multiple-imputation, competing-risk, and alternative missing-data analyses examine important sources of uncertainty.

↳ Randomisation and masking; Adjudication and cognitive outcomes; Statistical analysis

#positioning

Discussion directly engages divergent trial findings

The Discussion examines differences from SPRINT MIND and ACCORD MIND rather than treating the results in isolation. It considers baseline cognitive status, follow-up duration, and possible medication-related explanations for differing brain-volume findings.

↳ Discussion, Comparison with other studies

Limitations

#methodological rigour

MRI inference depends on incomplete selected follow-up

Only 605 of 862 participants completed repeat MRI, leaving selection and imputation assumptions important to the positive finding. Table 4 labels follow-up populations as 419 and 428 rather than 302 and 303 observed scans, and its printed asinh formula is incorrect, limiting reproducibility without proving an analysis error.

↳ Results, MRI outcomes; Figure 5; Table 4 and footnote

#methodological rigour

Adverse-event results are not reported here

This analysis describes safety monitoring but does not present systematic adverse-event results. Its cognitive findings therefore cannot independently establish the overall benefit-harm balance of intensive treatment.

↳ Methods, Study design and participants; Results; Introduction, reference to the primary cardiovascular report

#methodological rigour

Cognitive inference remains bounded by ascertainment

Mild cognitive impairment was operationalised through persistent decline from each participant's baseline, introducing uncertainty about endpoint sensitivity. A median 3.8 years of follow-up also leaves delayed cognitive effects unresolved.

↳ Adjudication and cognitive outcomes; Discussion, Comparison with other studies and Research implications

Does this match your read? Add your assessment ↓

Nabu Commentary

The trial addresses an important diabetes-specific evidence gap through a large randomised comparison with masked cognitive adjudication and sufficient composite events for its planned effect size. The primary result supports no statistically significant difference over 3.8 years, not equivalence or a definitive conclusion about longer-term effects. The MRI finding is less secure because selected participation and missing repeat scans leave weighting and imputation assumptions consequential, while Table 4 contains unresolved reporting details. The Discussion substantively engages prior trials, but absent adverse-event results restrict this report's standalone assessment of treatment safety.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.1±0.1

Contribution
4.4

The large randomised comparison supplies adjudicated clinical cognitive outcomes in adults with type 2 diabetes, addressing a population and endpoint gap left by SPRINT MIND and ACCORD MIND. Its advance is bounded by the 3.8-year observation period and the separate, selected nature of the positive imaging result.

Introduction; Statistical analysis; Table 2; Discussion, Research implications
Methodological Rigour
3.8

Central randomisation, masked adjudication, achieved event accrual, and missing-data and competing-risk analyses support the cognitive comparison, while endpoint operationalisation and MRI selection and missingness introduce uncertainty. Absent adverse-event results reduce reporting completeness, and the incorrect transformation formula limits reproducibility without demonstrating an erroneous estimate.

Randomisation and masking; Adjudication and cognitive outcomes; Modifications to protocol after start of trial; Statistical analysis; Tables 2 and 4
Reporting
4.0

The organisation and primary conclusion distinguish a nonsignificant cognitive comparison from the positive imaging result. Cognitive-safety phrasing and the less explicit qualification of imaging findings in the abstract prevent the consistently precise interpretation required for a higher score.

Abstract Conclusions; What this study adds; Discussion, Comparison with other studies and Research implications
Positioning
4.4

The Discussion engages the different populations, cognitive results, and brain-volume findings of the closest trials and connects multiple limitations to interpretation. The consequences of the higher-than-expected composite event rate and MRI follow-up loss receive less explicit treatment.

Introduction; Discussion, Comparison with other studies; Strengths and limitations of this study

Lower confidence on Methodological Rigour — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • "Follow-up(95% CI); n=419" (Table 4, Follow-up column header) vs "605 (70.2%) participants completed a repeat MRI scan (302 intensive treatment v 303 standard treatment)" (Results, MRI outcomes). Table 4 labels follow-up populations as 419/428 rather than the 302/303 observed repeat scans, without explicitly identifying the headers as imputed analysis populations. The effect on the result is unclear.
Reporting and transparencyNoted

The printed inverse hyperbolic sine formula is incorrect, leaving the implemented transformation uncertain from the description alone. Ethics approval, consent, registration, competing interests, and a named data and code repository are declared.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared · Code availability: declared

Reference IntegrityNoted

43 references in manuscript 39 of 39 checkable references found in an index 4 could not be checked — not the same as no match found 4 mistyped DOIs matched to the cited work by its details

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 19 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary cognitive claim is tested in a large multicentre randomised trial across 145 centres with adjudicated outcomes, confirming the result in a real clinical population.

From the paper
“incorporated into relevant national and international guidelines to inform clinicians”

The paper names guideline bodies and clinicians as actors who would use the findings to inform blood pressure treatment decisions for adults with type 2 diabetes.

Pathway

Cardiologists, diabetologists and guideline bodies setting blood pressure targets for adults with type 2 diabetes would use these findings to justify intensive SBP control.

Barrier

The null cognitive finding and single-country Chinese population mean guideline bodies will want confirmation in other ethnic populations before changing targets.

Evaluated 19 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Smoking and dementia risk: an updated systematic review and meta-analysis of 61 prospective cohort studies and implications for tobacco control

    Mario Siervo, Jacob Brain, Sarah Beasley, et al. · 2026 · Health sciences

    Primary claim

    Current smoking was associated with increased risk of all-cause dementia (RR 1.31 [95% CI 1.23–1.39]; number of studies (k) = 39), Alzheimer's disease (1.40 [1.08–1.80]; k = 15), and vascular dementia (1.52 [1.20–1.93]; k = 9).

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  2. Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    2026 · Clinical medicine

    Primary claim

    decreased ACD was associated with greater AD pathological burden

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats
  3. The potential of low-field MRI for global dementia care

    2026 · Clinical medicine

    Primary claim

    Studies demonstrate reliable detection of core Alzheimer disease markers, including hippocampal atrophy and white matter hyperintensities, on portable low-field systems, with promising correspondence to conventional high-field MRI findings.

    Tentative
    Evidence Score
    3.7±0.1
    Reliability
    Caveats

How the rubric works →